Devices And Methods For Ophthalmic Drug Delivery
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an eye of the subject with an ophthalmic drug delivery device comprising a body having a proximal end and a distal end, wherein the body comprises a styrene elastomer matrix and a drug in contact with the matrix, wherein release of the drug from the device occurs over time following contacting of the device with the eye of the subject.
-
Citations
36 Claims
-
1-13. -13. (canceled)
-
14. A method of treating or preventing an eye disease in a subject, comprising:
-
contacting an eye of the subject with an ophthalmic drug delivery device comprising; a body configured to be inserted into the subject in the proximity of the eye, the body including a styrene elastomer matrix; and a drug in contact with the matrix; wherein the drug is released from the device over time following the contacting. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 31)
-
-
25. A method of treating or preventing an eye disease in a human subject, comprising:
-
contacting an eye of the human subject with an ophthalmic drug delivery device comprising; i. a body configured to be inserted into the subject in the proximity of the eye, the body formed entirely of a styrene elastomer matrix wherein the styrene elastomer matrix comprises a copolymer selected from the group consisting of styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene block copolymer (SBS), styrene-isoprene-butadiene-styrene block copolymer (SIBS), styrene-ethylene-butylene-styrene block copolymer(SEBS), and styrene-ethylene-propylene-styrene block copolymer (SEPS); and ii. a drug dispersed within the with the matrix; wherein the drug is released from the device over time following the contacting and wherein the eye disease is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, retinal neovascularization, subretinal neovascularization;
rubeosis irides, retinitis, choroiditis, posterior uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma;
neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases, retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streaks, retinal artery occlusion, and neovascularization due to ocular injury and wherein the contacting includes inserting the body of the device into the subject in the proximity of the eye such that a distal end of the device is extended toward a posterior segment of the eye. - View Dependent Claims (26, 27, 28, 29, 30)
-
-
32. A method of treating or preventing an eye disease in a human subject, comprising:
-
re-heating and shaping a body of an ophthalmic drug delivery device after examination of an eye of the human subject, the body being formed entirely of a styrene elastomer matrix with a drug dispersed within the matrix wherein the styrene elastomer matrix comprises a copolymer selected from the group consisting of styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene block copolymer (SBS), styrene-isoprene-butadiene-styrene block copolymer (SIBS), styrene-ethylene-butylene-styrene block copolymer(SEBS), and styrene-ethylene-propylene-styrene block copolymer (SEPS) and wherein the body has a length of about 10 mm to about 30 mm and a diameter of about 0.1 mm to about 5 mm.; and contacting the eye of the subject with the ophthalmic drug delivery device immediately after re-heating and shaping by inserting the body of the device into the subject in the proximity of the eye such that a distal end of the device is extended toward a posterior segment of the eye, the body including a styrene elastomer matrix; wherein the device remains within the eye for a time period of week and drug is released from the device over the time period of weeks following the contacting and wherein the eye disease is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, retinal neovascularization, subretinal neovascularization;
rubeosis irides, retinitis, choroiditis, posterior uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma;
neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases, retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streaks, retinal artery occlusion, and neovascularization due to ocular injury and wherein the contacting comprises implanting the device in a subconjunctival and sub-Tenon'"'"'s location in the subject and wherein the drug is selected from the group consisting of an anti-angiogenesis agent, an anti-glaucoma agent, an anti-infective agent, a nonsteroidal anti-inflammatory agent, a growth factor, an immunosuppressant agent, and an anti-allergic agent. - View Dependent Claims (33, 34, 35, 36)
-
Specification